The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, KalVista Pharmaceuticals Inc’s stock clocked out at $11.27, up 3.68% from its previous closing price of $10.87. In other words, the price has increased by $3.68 from its previous closing price. On the day, 0.82 million shares were traded.
Ratios:
To gain a deeper understanding of KALV’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.87 and its Current Ratio is at 6.87. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on January 31, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $19.
On January 07, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $30.
On December 18, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $22.BofA Securities initiated its Buy rating on December 18, 2024, with a $22 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 24 ’25 when Audhya Paul K. sold 2,394 shares for $10.02 per share. The transaction valued at 23,988 led to the insider holds 102,940 shares of the business.
Yea Christopher sold 1,918 shares of KALV for $19,218 on Feb 24 ’25. The CHIEF DEVELOPMENT OFFICER now owns 93,952 shares after completing the transaction at $10.02 per share. On Feb 18 ’25, another insider, Yea Christopher, who serves as the CHIEF DEVELOPMENT OFFICER of the company, sold 2,601 shares for $9.82 each. As a result, the insider received 25,553 and left with 92,745 shares of the company.
Stock Price History:
Over the past 52 weeks, KALV has reached a high of $15.50, while it has fallen to a 52-week low of $7.30. The 50-Day Moving Average of the stock is 22.94%, while the 200-Day Moving Average is calculated to be 1.84%.
Shares Statistics:
A total of 43.27M shares are outstanding, with a floating share count of 38.34M. Insiders hold about 22.42% of the company’s shares, while institutions hold 89.26% stake in the company.
Earnings Estimates
A detailed examination of KalVista Pharmaceuticals Inc (KALV) is currently in progress, with 9.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.91, with high estimates of -$0.81 and low estimates of -$1.02.
Analysts are recommending an EPS of between -$0.92 and -$4.04 for the fiscal current year, implying an average EPS of -$3.34. EPS for the following year is -$2.52, with 9.0 analysts recommending between -$0.5 and -$3.75.
Revenue Estimates
Based on 10 analysts’ estimates, the company’s revenue will be $45.94M in the next fiscal year. The high estimate is $85.21M and the low estimate is $18.12M.
